

## **LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) An isolated peptide marker binding specifically to nasopharyngeal carcinoma (NPC) cells, wherein the amino acid sequence of the peptide marker comprises an amino acid sequence as set forth in SEQ ID NO:1.
2. (Previously presented) A liposome comprising the peptide marker of claim 1.
3. (Previously presented) A chemotherapeutic drug comprising the peptide marker of claim 1, wherein the chemotherapeutic drug binds to NPC cells specifically.
4. (Original) A chemotherapeutic drug according to claim 3, wherein the chemotherapeutic drug comprises doxorubicin.
5. (Previously presented) An isolated peptide marker according to claim 1, wherein the peptide marker comprises the ability to lead a liposome to NPC cells.
6. (Previously presented) An isolated peptide marker according to claim 5, wherein the peptide marker guides the liposome to the NPC cell and enters nasopharyngeal carcinoma cells through endocytosis.
7. (Previously presented) An isolated peptide marker according to claim 1, wherein the peptide marker is applied as a detector in the development of an NPC cell diagnosis kit.
8. (Previously presented) A complex targeted specifically to NPC cells comprising an isolated peptide marker, wherein the amino acid sequence of the peptide marker comprises an amino acid sequence as set forth in SEQ ID NO:1.

9. (Original) A complex according to claim 8, wherein the complex comprises a chemotherapeutic drug.

10. (Original) A complex according to claim 9, wherein the chemotherapeutic drug comprises doxorubicin.

11. (Original) A complex according to claim 8, wherein the complex comprises a liposome.

12. (Original) A chemotherapeutic drug complex according to claim 8, wherein the complex enters NPC cells through endocytosis.

Claims 13-16 (Canceled)